GENE ONLINE|News &
Opinion
Blog

2022-04-18| COVID-19

WHO report highlights the role of Traditional Chinese Medicine in the treatment of COVID-19

by GeneOnline
Share To

BEIJING, April 18, 2022 /PRNewswire/ — A news report by haiwainet.cn:

On March 31, World Health Organization released the meeting report of “WHO Expert Meeting on Evaluation of Traditional Chinese Medicine (TCM) in the Treatment of COVID-19” on its official website. The report acknowledged that on the basis of clinically relevant outcome measures, the studied TCMs are beneficial in the treatment of COVID-19, particularly in mild-to-moderate cases. WHO encourages Member States to consider the integration of traditional medicine interventions such as TCM in planning for the clinical management of COVID-19 in the context of their healthcare systems and regulatory frameworks.

The report pointed out that in the process of treating COVID-19, there are promising data to suggest that TCM is beneficial in reducing the risk of progression from mild-to-moderate cases to severe COVID-19. When administered as add-on interventions to conventional treatment, TCM may shorten the time for viral clearance, resolution of clinical symptoms, and length of hospital stay when compared to conventional treatment alone.

The report recommends that WHO should share the outcomes of this consultation with Member States in a timely manner given the evolving nature of COVID-19 globally. Member States are encouraged to consider the potential use of TCM for the management of COVID-19 in the context of their healthcare systems and regulatory frameworks; share experiences and lessons, particularly those actively acquired through this organized research programme in TCM and clinical experience from China.

Yu Wenming, head of China’s National Administration of Traditional Chinese Medicine, said China is willing to assist other WHO Member States to strengthen the role of traditional medicine in their health systems.

As of March 2022, the Chinese Clinical Trials Registry, which is part of WHO’s ICTRP (International Clinical Trials Registry Platform), showed 859 clinical studies of COVID-19 in China. Among these Chinese clinical trials, 213 relate to TCM.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Lunit AI Solutions to Power Samsung’s X-ray Devices for Advanced Chest Screening
2024-01-16
FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy
2023-12-24
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications
2023-12-17
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top